Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Champions Oncology Inc's Business Segments
Champions Oncology Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
3
Largest Segment
Pharmacology services
Total Revenue
$ 15
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Pharmacology services92.9%
- Translational Oncology Solutions (tos) License Revenue5.9%
- Product and Service, Other1.2%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Pharmacology services | $ 14 | 92.9% |
| Translational Oncology Solutions (tos) License Revenue | $ 1 | 5.9% |
| Product and Service, Other | $ 0 | 1.2% |
Annual Results
Revenue Share by Reportable Segment - FY
- Pharmacology services92.9%
- Translational Oncology Solutions (tos) License Revenue5.9%
- Product and Service, Other1.2%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Pharmacology services | $ 14 | 92.9% |
| Translational Oncology Solutions (tos) License Revenue | $ 1 | 5.9% |
| Product and Service, Other | $ 0 | 1.2% |
Revenue by Product & Service Category - FY
- Pharmacology services96.1%
- Product and Service, Other2.6%
- Translational Oncology Solutions (tos) License Revenue1.3%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Pharmacology services | $ 57 | 96.1% |
| Product and Service, Other | $ 2 | 2.6% |
| Translational Oncology Solutions (tos) License Revenue | $ 1 | 1.3% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Champions Oncology Inc
Champions Oncology Inc is a leading company in the field of personalized oncology solutions. It was founded in 2007 and is headquartered in Hackensack, New Jersey. The company specializes in developing and providing advanced technology solutions and services that help doctors and researchers in the fight against cancer.
Champions Oncology operates four main business units, which include:
1. TumorGraft Testing Services: This unit offers services that involve growing patients' tumor cells in the lab and testing their response to different drugs. This helps oncologists identify the most effective treatment options and personalize the therapy for individual patients.
2. Clinical Trials Services: Champions Oncology provides a wide range of services for pharmaceutical and biotech companies conducting clinical trials. These services include patient-derived xenograft (PDX) studies, biomarker analysis, and preclinical drug development.
3. Data Solutions: The company has developed a proprietary database called the Champions TumorGraft Database (CTD). It includes a wide range of information, such as patient treatment histories, genomic data, and drug response data. This database is a valuable resource for researchers and clinicians, enabling them to access and analyze comprehensive oncology data.
4. Immuno-Oncology Services: Champions Oncology offers services related to immuno-oncology research, which involves studying the interactions between the immune system and cancer cells. These services include preclinical testing of immuno-oncology therapeutics and the development of patient-derived models for immuno-oncology research.
Champions Oncology has a team of experienced scientists, oncologists, and technicians who work together to provide high-quality services and solutions. The company has established partnerships with leading cancer centers, academic institutions, and pharmaceutical companies to collaborate on research and development projects.
The ultimate goal of Champions Oncology is to improve patient outcomes and revolutionize cancer treatment through the use of personalized medicine. By leveraging their expertise in tumor biology, genomics, and data analytics, they aim to empower healthcare providers with the necessary tools and insights to make informed clinical decisions.
In summary, Champions Oncology Inc is a dynamic and innovative company at the forefront of personalized oncology solutions. Through their various service offerings and collaborations, they are making significant contributions to advancing cancer research and improving patient care.
Champions Oncology operates four main business units, which include:
1. TumorGraft Testing Services: This unit offers services that involve growing patients' tumor cells in the lab and testing their response to different drugs. This helps oncologists identify the most effective treatment options and personalize the therapy for individual patients.
2. Clinical Trials Services: Champions Oncology provides a wide range of services for pharmaceutical and biotech companies conducting clinical trials. These services include patient-derived xenograft (PDX) studies, biomarker analysis, and preclinical drug development.
3. Data Solutions: The company has developed a proprietary database called the Champions TumorGraft Database (CTD). It includes a wide range of information, such as patient treatment histories, genomic data, and drug response data. This database is a valuable resource for researchers and clinicians, enabling them to access and analyze comprehensive oncology data.
4. Immuno-Oncology Services: Champions Oncology offers services related to immuno-oncology research, which involves studying the interactions between the immune system and cancer cells. These services include preclinical testing of immuno-oncology therapeutics and the development of patient-derived models for immuno-oncology research.
Champions Oncology has a team of experienced scientists, oncologists, and technicians who work together to provide high-quality services and solutions. The company has established partnerships with leading cancer centers, academic institutions, and pharmaceutical companies to collaborate on research and development projects.
The ultimate goal of Champions Oncology is to improve patient outcomes and revolutionize cancer treatment through the use of personalized medicine. By leveraging their expertise in tumor biology, genomics, and data analytics, they aim to empower healthcare providers with the necessary tools and insights to make informed clinical decisions.
In summary, Champions Oncology Inc is a dynamic and innovative company at the forefront of personalized oncology solutions. Through their various service offerings and collaborations, they are making significant contributions to advancing cancer research and improving patient care.
Champions Oncology Inc. stands out as a prominent biotechnology company dedicated to advancing personalized cancer treatment through its innovative technology solutions. The firm specializes in a comprehensive array of segments, products, and services that cater to the specific needs of oncologists, pharmaceutical companies, and researchers engaged in the battle against cancer.
Segments
1. Predictive Oncology Services:
Champions Oncology offers state-of-the-art predictive oncology services aimed at accurately forecasting patient responses to various cancer treatments. This segment leverages sophisticated tumor models, particularly patient-derived xenograft (PDX) models, along with in vitro testing platforms. It allows for rigorous investigations into drug efficacy, helping clinicians and researchers understand how individual patients may respond to specific therapies.
2. Translational Oncology Solutions:
The translational oncology solutions segment focuses on bridging the gap between preclinical research and clinical application. Champions Oncology provides critical insights to optimize drug development strategies, identify suitable patient cohorts, and facilitate biomarker development tailored to enhance personalized cancer therapy. This segment plays a crucial role in ensuring that preclinical findings effectively translate into successful clinical outcomes.
Products
1. TumorGraft PDX Models:
The cornerstone of Champions Oncologys offerings is its extensive library of patient-derived xenograft (PDX) models. These models replicate the biological characteristics and behavior of the original patient tumors, serving as a reliable platform for testing various treatment modalities. By providing a more in-vivo representation of patient tumors, these models allow for precise evaluations of potential drug efficacy across different cancer types.
2. Biomarker Development and Analysis:
Champions Oncology excels in providing biomarker development and analysis services, crucial for identifying and validating biomarkers capable of predicting drug responses, diagnosing cancer, or monitoring treatment success. Their capabilities encompass a wide range of analytical techniques, including genomics, transcriptomics, proteomics, and immuno-oncology profiling, thus enabling researchers to craft more effective, tailored therapeutic approaches.
3. Cancer Cell Line Panel:
The company offers a robust panel of authenticated and clinically annotated human cancer cell lines that accurately reflect various tumor types. These cell lines are indispensable tools for cancer research, allowing for in-depth drug discovery efforts and preclinical testing. The clinical annotations associated with these cell lines provide additional context that enhances their utility in research and development.
Services
1. TumorGraft Clinical Trials:
Champions Oncology collaborates with pharmaceutical companies to conduct clinical trials based on its TumorGraft technology. These trials entail the engraftment of patient tumors into immunocompromised mice, facilitating the evaluation of investigational drugs. This approach not only accelerates the drug development process but also provides invaluable insights into the potential clinical efficacy of new therapies.
2. Personalized Oncology Solutions:
In an effort to deliver tailored treatment strategies, Champions Oncology offers personalized oncology solutions. Oncologists can send patient tumor samples to the company’s facility for in-depth testing and analysis. The results formed from this testing are used to devise personalized treatment plans, which significantly improve the likelihood of therapeutic success for individual patients.
3. Collaborative Research Projects:
Champions Oncology actively engages in collaborative research initiatives with academic institutions, research organizations, and pharmaceutical entities. These partnerships aim to further the understanding of cancer biology, improve therapeutic strategies, and uncover new treatment modalities. This collaborative spirit underscores the company’s commitment to advancing the field of oncology and enhancing patient outcomes.
Conclusion
In summary, Champions Oncology Inc. operates at the intersection of advanced biotechnological services and personalized cancer therapy. Through its extensive range of segments, innovative products like TumorGraft PDX models and cancer cell line panels, and diverse services—including clinical trials and personalized solutions—the company plays a pivotal role in the ongoing efforts to enhance cancer treatment and research. By harnessing cutting-edge technologies and deep scientific expertise, Champions Oncology is significantly contributing to the evolution of cancer care and research.
Segments
1. Predictive Oncology Services:
Champions Oncology offers state-of-the-art predictive oncology services aimed at accurately forecasting patient responses to various cancer treatments. This segment leverages sophisticated tumor models, particularly patient-derived xenograft (PDX) models, along with in vitro testing platforms. It allows for rigorous investigations into drug efficacy, helping clinicians and researchers understand how individual patients may respond to specific therapies.
2. Translational Oncology Solutions:
The translational oncology solutions segment focuses on bridging the gap between preclinical research and clinical application. Champions Oncology provides critical insights to optimize drug development strategies, identify suitable patient cohorts, and facilitate biomarker development tailored to enhance personalized cancer therapy. This segment plays a crucial role in ensuring that preclinical findings effectively translate into successful clinical outcomes.
Products
1. TumorGraft PDX Models:
The cornerstone of Champions Oncologys offerings is its extensive library of patient-derived xenograft (PDX) models. These models replicate the biological characteristics and behavior of the original patient tumors, serving as a reliable platform for testing various treatment modalities. By providing a more in-vivo representation of patient tumors, these models allow for precise evaluations of potential drug efficacy across different cancer types.
2. Biomarker Development and Analysis:
Champions Oncology excels in providing biomarker development and analysis services, crucial for identifying and validating biomarkers capable of predicting drug responses, diagnosing cancer, or monitoring treatment success. Their capabilities encompass a wide range of analytical techniques, including genomics, transcriptomics, proteomics, and immuno-oncology profiling, thus enabling researchers to craft more effective, tailored therapeutic approaches.
3. Cancer Cell Line Panel:
The company offers a robust panel of authenticated and clinically annotated human cancer cell lines that accurately reflect various tumor types. These cell lines are indispensable tools for cancer research, allowing for in-depth drug discovery efforts and preclinical testing. The clinical annotations associated with these cell lines provide additional context that enhances their utility in research and development.
Services
1. TumorGraft Clinical Trials:
Champions Oncology collaborates with pharmaceutical companies to conduct clinical trials based on its TumorGraft technology. These trials entail the engraftment of patient tumors into immunocompromised mice, facilitating the evaluation of investigational drugs. This approach not only accelerates the drug development process but also provides invaluable insights into the potential clinical efficacy of new therapies.
2. Personalized Oncology Solutions:
In an effort to deliver tailored treatment strategies, Champions Oncology offers personalized oncology solutions. Oncologists can send patient tumor samples to the company’s facility for in-depth testing and analysis. The results formed from this testing are used to devise personalized treatment plans, which significantly improve the likelihood of therapeutic success for individual patients.
3. Collaborative Research Projects:
Champions Oncology actively engages in collaborative research initiatives with academic institutions, research organizations, and pharmaceutical entities. These partnerships aim to further the understanding of cancer biology, improve therapeutic strategies, and uncover new treatment modalities. This collaborative spirit underscores the company’s commitment to advancing the field of oncology and enhancing patient outcomes.
Conclusion
In summary, Champions Oncology Inc. operates at the intersection of advanced biotechnological services and personalized cancer therapy. Through its extensive range of segments, innovative products like TumorGraft PDX models and cancer cell line panels, and diverse services—including clinical trials and personalized solutions—the company plays a pivotal role in the ongoing efforts to enhance cancer treatment and research. By harnessing cutting-edge technologies and deep scientific expertise, Champions Oncology is significantly contributing to the evolution of cancer care and research.